Literature DB >> 14654076

Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.

A Pardanani1, A V Hoffbrand, J H Butterfield, A Tefferi.   

Abstract

We used three to six courses of 2-chlorodeoxyadenosine (2-CdA) (2-h infusion at 0.14 mg/kg per day x 5 days) given over a period of 3-36 months to treat four patients with aggressive systemic mast cell disease (SMCD) that was resistant to interferon-alpha (IFN-alpha). Treatment with 2-CdA resulted in a major response in two patients and a good partial response in one other patient (75% overall response). Treatment was well tolerated and duration of remission in responding patients ranges from 2 months to 4+ years since the completion of treatment with 2-CdA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14654076     DOI: 10.1016/s0145-2126(03)00185-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  Advanced mast cell disease: an Italian Hematological Multicenter experience.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Morena Caira; Michela Rondoni; Maria Teresa Van Lint; Anna Candoni; Bernardino Allione; Chiara Cattaneo; Laura Marbello; Cecilia Caramatti; Enrico Maria Pogliani; Emilio Iannitto; Fiorina Giona; Felicetto Ferrara; Rosangela Invernizzi; Rosa Fanci; Monia Lunghi; Luana Fianchi; Grazia Sanpaolo; Pietro Maria Stefani; Alessandro Pulsoni; Giovanni Martinelli; Giuseppe Leone; Pellegrino Musto
Journal:  Int J Hematol       Date:  2008-11-26       Impact factor: 2.490

2.  Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

Authors:  D J DeAngelo; T I George; A Linder; C Langford; C Perkins; J Ma; P Westervelt; J D Merker; C Berube; S Coutre; M Liedtke; B Medeiros; D Sternberg; C Dutreix; P-A Ruffie; C Corless; T J Graubert; J Gotlib
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

Review 3.  Target Therapies for Systemic Mastocytosis: An Update.

Authors:  Mariarita Sciumè; Claudio De Magistris; Nicole Galli; Eleonora Ferretti; Giulia Milesi; Pasquale De Roberto; Sonia Fabris; Federica Irene Grifoni
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-11

4.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Authors:  Jason Gotlib; Animesh Pardanani; Cem Akin; Andreas Reiter; Tracy George; Olivier Hermine; Hanneke Kluin-Nelemans; Karin Hartmann; Wolfgang R Sperr; Knut Brockow; Lawrence B Schwartz; Alberto Orfao; Daniel J Deangelo; Michel Arock; Karl Sotlar; Hans-Peter Horny; Dean D Metcalfe; Luis Escribano; Srdan Verstovsek; Ayalew Tefferi; Peter Valent
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 5.  Mastocytosis: advances in diagnosis and treatment.

Authors:  Susan I Hungness; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

6.  Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.

Authors:  Magalie Joris; Sophie Georgin-Lavialle; Marie-Olivia Chandesris; Ludovic Lhermitte; Jean-François Claisse; Danielle Canioni; Katia Hanssens; Gandhi Damaj; Olivier Hermine; Mohammed Hamidou
Journal:  Case Rep Hematol       Date:  2012-09-10

7.  The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.

Authors:  Mohamad Jawhar; Juliana Schwaab; Manja Meggendorfer; Nicole Naumann; Hans-Peter Horny; Karl Sotlar; Torsten Haferlach; Karla Schmitt; Alice Fabarius; Peter Valent; Wolf-Karsten Hofmann; Nicholas C P Cross; Georgia Metzgeroth; Andreas Reiter
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941

8.  KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.

Authors:  Marta Lopes; Maria Dos Anjos Teixeira; Cláudia Casais; Vanessa Mesquita; Patrícia Seabra; Renata Cabral; José Palla-García; Catarina Lau; João Rodrigues; Maria Jara-Acevedo; Inês Freitas; Jose Ramón Vizcaíno; Jorge Coutinho; Luis Escribano; Alberto Orfao; Margarida Lima
Journal:  Case Rep Hematol       Date:  2018-02-18

Review 9.  Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.

Authors:  Cecilia Monaldi; Sara De Santis; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

Review 10.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.